More promising results for Mesoblast's stem cell therapies
This article was originally published in Scrip
Executive Summary
The Australian regenerative therapy company Mesoblasthas reported positive new clinical and preclinical data for its adult mesenchymal precursor cell (MPC) therapies in various orthopaedic and ophthalmic settings, paving the way for expanded clinical programmes and possible alliances.